JNJ vs MRK stock comparison
Johnson & Johnson vs. Merck & Co. · data as of November 13, 2026
Johnson & Johnson (JNJ) has a market value of about $687.9B, Merck & Co. (MRK) about $364.3B. Over their latest twelve months Johnson & Johnson had revenue of $99.3B and Merck & Co. $67.4B.
On our five checks Merck & Co. scores higher: 2.8 out of 5 (average) against 2.6 (average).
By area, the stronger company is Merck & Co. on future growth; Merck & Co. on track record; Johnson & Johnson on financial health.
Johnson & Johnson is cheaper on earnings (P/E 43.4 vs. 150.8), while Merck & Co. grew revenue faster over five years (9.4% vs. 2.7% a year).
Johnson & Johnson leads on 10 of the compared lines and Merck & Co. on 13.
Side by side
| JNJ | MRK | |
|---|---|---|
| Size and price | ||
| Market cap | $687.9B | $364.3B |
| Share price | $285.75 | $147.76 |
| Score | ||
| Overall score (of 5) | 2.6 | 2.8 |
| Value | 0 | 0 |
| Future growth | 0 | 2 |
| Track record | 4 | 5 |
| Financial health | 4 | 2 |
| Shareholder returns | 5 | 5 |
| Valuation | ||
| P/E (TTM) | 43.4 | 150.8 |
| Forward P/E | 25.1 | 17.6 |
| Price / free cash flow | 33.4 | 24.7 |
| Price / sales | 6.9 | 5.4 |
| EV / EBITDA | 26.7 | 32.5 |
| PEG | 2.91 | 7.10 |
| DCF value vs. price | −39% | −31% |
| Business | ||
| Revenue | $99.3B | $67.4B |
| Net income | $16.1B | $2.5B |
| Free cash flow | $20.6B | $14.7B |
| Net margin | 16.2% | 3.6% |
| Gross margin (5-yr avg.) | 69.1% | 73.4% |
| ROIC (5-yr avg.) | 16.6% | 16.3% |
| Growth | ||
| Revenue growth (1 yr) | 6.0% | 1.3% |
| Revenue growth (5 yrs, per year) | 2.7% | 9.4% |
| EPS growth (5 yrs, per year) | 14.9% | 21.2% |
| Balance sheet and payouts | ||
| Net cash (cash minus debt) | -$27.4B | -$44.1B |
| Dividend yield | 1.88% | 2.30% |
| Shareholder yield | 2.8% | 3.7% |
| Analysts | ||
| Upside to average target | −2% | +9% |
| Consensus rating | Buy | Buy |
Highlighted = the better figure on that line. Revenue, net income and free cash flow: JNJ TTM to September 27, 2026, MRK TTM to September 30, 2026. Not investment advice.
Frequently asked questions
Which is the better stock, Johnson & Johnson or Merck & Co.?
We do not give buy or sell advice. On our five checks (value, growth, track record, financial health and shareholder returns) Merck & Co. scores 2.8 out of 5 and Johnson & Johnson 2.6; the table shows where each one is stronger.
Is Johnson & Johnson cheaper than Merck & Co.?
On trailing earnings, Johnson & Johnson trades at a P/E of 43.4 and Merck & Co. at 150.8, so Johnson & Johnson is cheaper by this measure. A lower P/E can also reflect slower expected growth.
Which grows faster, Johnson & Johnson or Merck & Co.?
Over five years Merck & Co. grew revenue about 9.4% a year and Johnson & Johnson about 2.7% a year.
Which pays a higher dividend?
Johnson & Johnson yields 1.88% and Merck & Co. 2.30%.
Full Johnson & Johnson analysis → Full Merck & Co. analysis →
More comparisons
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.